Erlotinib hydrochloride

Nat Rev Drug Discov. 2005 Jan;4(1):13-4. doi: 10.1038/nrd1612.
No abstract available

Publication types

  • News

MeSH terms

  • Administration, Oral
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / epidemiology
  • Clinical Trials, Phase III as Topic
  • Docetaxel
  • Drug Administration Schedule
  • Drug Delivery Systems / methods
  • Drug Delivery Systems / trends*
  • Drug Design
  • Drug Screening Assays, Antitumor / methods
  • ErbB Receptors / classification
  • ErbB Receptors / drug effects
  • ErbB Receptors / metabolism
  • Erlotinib Hydrochloride
  • Expert Testimony
  • Humans
  • Quinazolines / chemistry
  • Quinazolines / pharmacology
  • Quinazolines / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Taxoids / therapeutic use
  • Time Factors
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Quinazolines
  • Taxoids
  • Docetaxel
  • Erlotinib Hydrochloride
  • ErbB Receptors